HT Partners LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 2.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,451 shares of the company’s stock after acquiring an additional 323 shares during the period. Johnson & Johnson accounts for approximately 0.8% of HT Partners LLC’s investment portfolio, making the stock its 14th biggest holding. HT Partners LLC’s holdings in Johnson & Johnson were worth $2,432,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Newfound Research LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $28,000. Essex Investment Management Co. LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $37,000. Crewe Advisors LLC grew its position in Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock worth $50,000 after purchasing an additional 300 shares during the period. Dimension Capital Management LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $53,000. Finally, IMA Wealth Inc. grew its position in Johnson & Johnson by 26.8% during the 3rd quarter. IMA Wealth Inc. now owns 478 shares of the company’s stock worth $71,000 after purchasing an additional 101 shares during the period. 61.26% of the stock is currently owned by hedge funds and other institutional investors.
In related news, COO Michael E. Sneed sold 54,662 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total value of $8,359,459.66. Following the completion of the sale, the chief operating officer now owns 110,741 shares in the company, valued at approximately $16,935,621.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is currently owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same quarter last year, the firm earned $2.12 EPS. The business’s revenue was up 1.7% compared to the same quarter last year. On average, research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 9th. Investors of record on Tuesday, February 23rd will be issued a $1.01 dividend. The ex-dividend date is Monday, February 22nd. This represents a $4.04 annualized dividend and a yield of 2.56%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Several equities research analysts have weighed in on the company. Cantor Fitzgerald increased their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. BidaskClub raised shares of Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 6th. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Finally, Morgan Stanley increased their target price on shares of Johnson & Johnson from $170.00 to $178.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 15th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $165.50.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: Why does the United States have a lingering trade deficit?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.